Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Candin · 3 trials · 1 indication
Number of participants with presence and size of induration in active versus control at the Candin injection site compared to the intra-individual saline control injection site between 6 and 96 hours after Candin challenge will be reported.
Number of participants with presence and size of induration in active versus control at the Candin injection site compared to the intra-individual saline control injection site approximately 48 hours after Candin challenge will be reported.
| Arm | Type | Description |
|---|---|---|
| Candin + Cosentyx | EXPERIMENTAL | Participants will receive a single dose of candin injection intradermally on Day 6 along with a single dose of saline solution injection of 0.9 percent (%) sodium chloride (NaCl) and a single dose of Cosentyx injection subcutaneously on Day 1. |
| Candin Challenge | NO_INTERVENTION | All participants will receive single dose of candin injection intradermally on Day 6 along with a single dose of saline solution injection of 0.9 percent (%) sodium chloride (NaCl) administered intradermally and no Cosentyx. |
| Active Arm: Benlysta + Candin | ACTIVE_COMPARATOR | Participants will receive a single dose of Candin injection intradermally along with a saline solution of 0.9% sodium chloride (NaCl), and a single dose of Benlysta injection subcutaneously. |
| Control Arm: Candin | NO_INTERVENTION | All participants will receive a single dose of Candin injection intradermally along with a single dose of saline solution of 0.9% NaCl administered intradermally and no Benlysta. |
| Active Arm: Candin + Consentyx | ACTIVE_COMPARATOR | Participants will receive a single dose of Candin injection intradermally along with a saline solution of 0.9% sodium chloride (NaCl), and a single dose of Cosentyx injection subcutaneously. |
| Name | Type | Description |
|---|---|---|
| Cosentyx | DRUG | Cosentyx injection will be administered subcutaneously. |
| Candin | DRUG | Candin will be administered interadermally along with NaCl solution. |
| Benlysta | DRUG | Benlysta injection will be administered subcutaneously. |
Inclusion Criteria: * Have a body mass index (BMI) between 18 and 30 kilograms per meter square (kg/m\^2) (BMI = weight/height\^2), inclusive, and a body weight of no less than 50 kilograms (kg) * Otherwise healthy on the basis of physical examination, medical history, and vital signs, and if requi...
Candin is an investigational small molecule developed by Johnson & Johnson (ticker JNJ). It is being studied as a challenge agent in healthy participants rather than as a treatment for a specific disease. All three of its Phase 1 trials have been completed, and no active trials are currently listed.
Candin is used as a challenge agent in clinical research involving healthy participants. Its completed Phase 1 trials were conducted in healthy volunteers in Belgium, with no disease indication disclosed. It is not described as a treatment for any specific condition, and no therapeutic indication has been announced.
Candin is developed by Johnson & Johnson, which trades under the ticker JNJ. The company has sponsored all three of the completed Phase 1 trials of Candin, which were run in Belgium and enrolled a combined total of 45 healthy participants.
Candin is in Phase 1 development. All three of its clinical trials are Phase 1 studies, and all three are completed, with no active trials listed. It is an investigational agent and has not been approved by the FDA for any use.
Candin has been studied in three completed Phase 1 trials: NCT05522517, which enrolled 20 healthy participants; NCT04611971, which enrolled 13; and NCT04589026, which enrolled 12. All three were conducted in Belgium in healthy volunteers aged 18 and older, and all are now completed.
Candin is a small molecule studied as a challenge agent in healthy participants. In that role it is given to volunteers to help evaluate a biological response under controlled research conditions. Its specific molecular target has not been disclosed, so its precise mechanism of action is not publicly described.